---
layout: default
title: Alpha -Tocopherol Aloe Witch Hazel Zinc Oxide
parent: 僅模型預測 (L5)
nav_order: 243
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Aloe Witch Hazel Zinc Oxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha-Tocopherol / Aloe / Witch Hazel / Zinc Oxide: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This entry represents a multi-ingredient combination product containing Alpha-Tocopherol (Vitamin E), Aloe, Witch Hazel, and Zinc Oxide — ingredients commonly found in topical skin-care or wound-care formulations.
The TxGNN model returned **no predicted new indications** for this combination, and the product has **no registered licenses** in the US market.
Without a DrugBank ID, confirmed approved indication, or model output, a standard repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no registered licenses found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no actual studies identified |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this entry, so a mechanistic rationale for a new indication cannot be provided.

The queried drug string (`.ALPHA.-TOCOPHEROL; ALOE; WITCH HAZEL; ZINC OXIDE`) represents a fixed-dose combination of four ingredients rather than a single molecular entity. The TxGNN knowledge graph is optimized for individual drugs with a confirmed DrugBank node; multi-ingredient combination strings of this format typically do not match any single node in the graph, which explains the empty prediction result.

Currently, detailed mechanism of action data is not available. Based on known pharmacology, the individual components — Vitamin E (antioxidant), Aloe (emollient/anti-inflammatory), Witch Hazel (astringent/antioxidant), and Zinc Oxide (barrier/antiseptic) — are each used in topical dermatological applications. Mechanistically, a repurposing hypothesis would require the combination to first be decomposed into individual active ingredients and each queried separately.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination query.

---

## Literature Evidence

Currently no related literature available for this combination query.

---

## US Market Information

No US licenses found for this combination string.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predictions, no regulatory licenses, and no usable safety or efficacy data, making it impossible to conduct a meaningful repurposing evaluation at this stage.

**To proceed, the following is needed:**

- **Decompose the combination query** — Re-query each active ingredient individually (Alpha-Tocopherol, Aloe extract, Witch Hazel extract, Zinc Oxide) to obtain separate TxGNN prediction scores and evidence packs.
- **Obtain a DrugBank ID** — At minimum for Alpha-Tocopherol (DrugBank: DB00162) and Zinc Oxide (DrugBank: DB09341), which have known nodes in the knowledge graph.
- **Clarify the intended dosage form and route** — Confirm whether this is a topical product; if so, systemic repurposing models (TxGNN) may not be the appropriate evaluation framework.
- **Confirm the original approved indication** — Search TFDA, FDA, or EMA databases using individual ingredient names to establish a regulatory baseline.
- **Retrieve safety data** — Download the relevant package insert PDFs to populate the key warnings and contraindications fields before any safety evaluation can proceed (DG001).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

